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Introduction
Colorectal cancer (CRC) is the second leading cause of 
cancer deaths in the Western world with a million new 
cases diagnosed each year. Although a small subset of these 
cases are well-characterized hereditary syndromes, the vast 
majority of CRCs are considered non-familial occurring 
in individuals with genetic susceptibility as a result of the 
interaction between environmental exposures and multiple 
genes with low penetrance. Advances in early detection and 
surgery have been largely responsible for reducing mortality 
and morbidity of colon cancer and our understanding of 
prevention is increasing. Diet is an important environmental 
factor in the etiology of CRC and epidemiological data 
generally support the association between total energy 
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Evidence that has accumulated for many years suggests that diet is 
an important environmental factor in the etiology of colorectal 
cancers. Epidemiological data generally support the association 
between total energy intake, high fat diets, red meat intake and 
increased colon cancer risk. The Western-style diet and cooking 
techniques are risk factors for developing colon cancer. Further, 
oxidative stress caused by reactive oxygen species plays a 
significant role in a number of age-specific diseases such as cancer 
and neurodegenerative disorders. Dietary proteins including whey 
proteins have been reported to have the ability to scavenge reactive 
oxygen species. Animal studies have also shown that whey protein 
protects against the development of carcinogen induced colon 
tumors in rats. In addition to proteins, protein hydrolyzates have 
been found to exhibit antioxidant activity. During protein 
hydrolysis, overall antioxidant activity of protein is enhanced as its 
tertiary structure is disrupted and the solvent accessibility of 
released amino acids increases.  In this review, we summarize the 
present knowledge on the etiopathogenesis of colorectal cancers 
and the potential use of whey proteins in its treatment.
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ÖZET 
Kolorektal kanser etiyolojisinde diyetin önemli bir çevresel faktör 
olduğu yapılan çalışmalarla kanıtlanmıştır. Total enerji alımı, 
yüksek yağlı diyet ve kırmızı et alımı ile kolon kanseri gelişimi 
arasında bağlantı  olduğu epidemiyolojik veri lerle de 
desteklenmiştir. Batı tarzı diyet ve pişirme teknikleri kolon kanseri 
için risk faktörü olarak yer almaktadır. Öte yandan, reaktif oksijen 
türleri tarafından oluşturulan oksidatif stres, kanser ve 
nörodejeneratif bozukluklar gibi yaşa bağlı hastalıklarda önemli rol 
oynamaktadır. Süt serumu proteinleri ve diğer diyetsel proteinlerin 
reaktif oksijen radikallerini temizleme gücüne sahip olduğu 
bildirilmiştir. Hayvan çalışmalarında karsinojen kullanılarak 
oluşturulan kolon kanserine karşı süt serumu proteinlerinin 
koruyucu olduğu gösterilmiştir. Proteinlerin yanında protein 
hidrolizatlarının da antioksidan aktivite gösterdiği bulunmuştur. 
Protein hidrolizi sırasında proteinin tersiyer yapısının bozulması ve 
amino asit salınmasındaki artışa bağlı olarak proteinin antioksidan 
aktivitesinde artış izlenmektedir. Bu derlemede, kolorektal kanser 
etiyopatogenezindeki mevcut bilgileri özetlemeye ve tedavide süt 
serumu proteinlerinin potansiyel kullanımını irdelemeye çalıştık.
Anahtar kelimeler: Serbest radikaller, Süt serumu proteinleri, 
Kolorektal kanser
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intake, high fat diets, red meat intake and increased colon 
cancer risk. Western-style diet and cooking techniques are 
risk factors for developing colon cancer [1,2].
Oxidative stress caused by reactive oxygen species plays 
a significant role in a number of age-specific diseases such 
as cancer and neurodegenerative disorders [3,4]. Dietary 
proteins including whey proteins have the ability to scavenge 
reactive oxygen species [5,6]. Animal studies have shown 
that whey protein protects against carcinogen induced colon 
tumors in rats [7,8]. In addition to proteins, protein 
hydrolyzates have also been found to exhibit antioxidant 
activity. During protein hydrolysis, overall antioxidant 
activity of protein is enhanced as its tertiary structure is 
disrupted and the solvent accessibility of released amino 
acids increases [9]. 
Free radicals and cancer 
Free radicals are defined as molecules which contain 
an unpaired electron in their outermost orbital. To stabilize 
the unpaired electron, free radicals will tend to donate 
or receive an electron by interacting with molecules in 
their environment. Uncontrolled generation of radicals 
and related reactants are deleterious to cell structure and 
function because they will react with macromolecules such 
as unsaturated lipids, proteins and nucleic acids [3,4]. 
Oxygen derived free radicals are: hydroxyl radicals 
(OH.), hydrogen peroxide (H2O2), hypochlorous acid (HOCl), 
singlet oxygen (O2), peroxynitrite anion (ONOO) and 
peroxynitrous acid (OHOOH). In most cells enzymes such as 
superoxide dismutase, glutathione peroxidase, glutathione 
reductase, glutathione transferase and catalase protect cells 
against free radicals. In addition, agents such as vitamin E, 
cysteine , glutathione  (GSH) and ceruloplasmin protect cells 
by inhibiting free radical formation or will inactivate them. 
The definitive effect of free radicals is related to the balance 
between their destruction and formation. If formation of free 
radicals exceeds the antioxidant defense mechanisms then a 
condition termed oxidative stress arises [10].
Detection  of harmful effects caused by free radicals 
in the ce l l are measured as markers of lipid, protein and 
DNA oxidation or intermediate products. Hydroxyl radicals 
primarily interact with unsaturated fatty acids of membrane 
phospholi p ids, starting oxidative damage. During lipid 
peroxidat ion biologically active intermediates are formed. 
The well k nown end product of lipid peroxidation is 
malondial d ehyde (MDA) which is itself cytotoxic. 
Measurement of the amount of MDA is a common method 
of assess ing oxidative damage. When lipid peroxidation 
is not bl o cked, increased membrane permeability, cell 
membrane d amage, decreased fluidity, imbalance of 
transmemb r ane ions, corruption of secretory functions 
emerge and lead to cell swelling and death [11].
GSH is a water-soluble tripeptide made up of glutamine, 
cysteine and glycine [12]. The potency of GSH exists in 
its cysteine residue  (thiol group). It is the most important 
thiol ant ioxidant in the organism and protects the body 
against electrophilic, halogenated structures and epoxides. 
GSH is involved in many direct and indirect protective 
mechanism s  [13]. It is  an important antioxidant that 
provides a  balance between oxidation and reduction, as 
well as protecting cells from harmful effects of endogenous 
and exogenous oxidants .  This protection is carried out 
by GSH S- t ransferase and GSH peroxidase. In addition 
to detoxi f ication, red u ction of ribonucleic acids to 
deoxyribonucleotides in  the glyoxalase system as well 
as gene expression of various proteins are also involved 
through the thiol group [12,13]. 
De novo synthesis of GSH requires the presence of 
cysteine, glutamic acid and glycine. Enzymes involved in 
the synthesis are g-glutamylcysteine synthetase and GSH 
synthetas e . GSH is con v erted to glutathione disulfide 
(oxidized  glutathione,  GSSG) by a selenium-containing 
enzyme, G S H peroxidase .  This enzyme catalyzes the 
reduction  of hydrogen p eroxide and other peroxides. 
GSSG, is a lso produced after reaction of GSH with free 
radicals.  Reduction of  GSSG back to GSH is catalyzed 
by GSH re d uctase in th e  presence of NADPH. In the 
extracellular space, GSH is converted to GSSG and this 
reaction requires oxygen causing the formation of hydrogen 
peroxide [14]. 
Cancer is one of the leading causes of death worldwide, 
and understanding the factors that contribute to cancer 
development may facilitate strategies for cancer prevention 
and control [15,16]. Cancer development involves genetic 
and epigenetic alterations. Nutrients can either contribute 
directly to cancer prevention or support the repair of genomic 
and epigenomic damage caused by exposure to cancer-
causing agents such as toxins, free radicals, radiation, and 
infectious agents. One of the earliest lines of evidence for 
the involvement of free radicals in carcinogenesis was 
chromosome fragmentation induced by hydrogen peroxide 
in the presence of a peroxidation factor [17]. Involvement 
of free radicals in carcinogenesis was further supported by 
several in vitro studies describing the role of free radicals 
in DNA damage as well as in structural and functional 
modifications of proteins [18-20]. 
Free radi c al related mutagenesis that can result 
in cancer  initiation and progression is a frequent event 
in normal  human cells. Although free radical mediated 
tumor promotion has not been directly demonstrated in 
humans, there is convincing experimental evidence that 
oxidative  stress can differentially induce the proliferation 
of tumor cells. Thus, oxygen derived free radicals should 
be recogn ized as an important class of carcinogens that 
stimulate cancer development at multiple stages [21].
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Several m o lecules present in the diet, including 
flavonoid s , can inhibit the growth of cancer cells with 
their abi l ity to act in chemoprevention. Recent research 
has revea l ed that these molecules possess antioxidant 
activities  which prevent free radical damage to biological 
molecules  like lipids, proteins and DNA, damage which 
can cause  many cardiovascular and neurodegenerative 
diseases as well as cancer and diabetes [22]. The underlying 
mechanisms involve metal chelation, a  capacity to act as 
a free rad ical scavenger and inhibition of enzymes that 
produce free radicals . Cancer preventive effects have also 
been attr ibuted to the induction of cell-cycle arrest and/
or apoptos is as well as the antioxidant functions. Since 
antioxidants are capable of preventing oxidative damage, 
the wide u se of natural food derived antioxidants is 
receiving greater attention as potential anticarcinogens [23].
  
Development of colorectal cancer
Colorectal carcinoma is one of the best-studied tumors 
in terms of its developmental mechanisms. Various studies 
have shown that large numbers of consecutive mutations 
finally create cancer. There is not a single mechanism in 
the development of colorectal cancer but several stages and 
multi-factorial mechanisms are effective [24-26]. Specific 
steps in a sequence are also required for tumor growth. 
Fearon and Vogelstein [27] proposed a model of colorectal 
carcinogenesis that correlates specific genetic changes with 
evolving tissue morphology (Figure 1). Over the past two 
decades, intense research has focused on elucidating the 
genetic defects and molecular abnormalities associated with 
the development and progression of colorectal adenomas and 
carcinomas. Mutations may cause activation of oncogenes 
(K-ras) and/or inactivation of tumor-suppressor genes 
[Adenomatous Plyposis Cli (APC),  Deleted in Colorectal 
Carcinoma (DCC) p53]. Colorectal carcinoma is thought to 
develop from adenomatous polyps by accumulation of these 
mutations. Defects in the APC gene were first described 
in patients with familial adenomatous polyposis (FAP). 
By investigating these families, characteristic mutations in 
the APC gene were identified. They are now known to be 
present in 80% of sporadic colorectal cancers as well. The 
APC gene is a tumor-suppressor gene. Mutations in both 
alleles are necessary for the initiation of polyp formation. 
The majority of mutations are premature stop codons, 
which result in a truncated APC protein. In FAP, the site 
of the mutation correlates with the clinical severity of the 
disease. For example, mutations in either the 3’ or 5’ end of 
the gene result in attenuated forms of FAP, while mutations 
in the center of the gene result in more virulent disease. 
Thus, knowledge of the specific mutation in a family may 
help guide clinical decisions [28].
APC inactivation alone does not result in carcinoma. 
Instead, this mutation sets the stage for the accumulation 
of genetic damage that results in malignancy via mutations 
accumulated in the loss of heterozygosity pathway [29-31]. 
Additional mutations involved in this pathway include 
activation of the K-ras oncogene and loss of the tumor 
suppressor genes DCC and p53. K-ras is classified as a 
proto-oncogene because mutation of only one allele will 
perturb the cell cycle. The K-ras gene product is a G protein 
involved in intracellular signal transduction. When active, 
K-ras binds guanosine triphosphate (GTP) and hydrolysis 
of GTP to guanosine diphosphate, and then inactivates 
the G protein. Mutation of K-ras results in an inability to 
hydrolyze GTP, thus leaving the G protein permanently 
in the active form. It is thought that this activation leads 
to uncontrolled cell division. A mutation associated with 
an increased risk of colorectal cancer was found in the 
MutY human homologue (MYH) gene on chromosome 1p. 
MYH is a base excision repair gene, and biallelic deletion 
results in changes in other downstream molecules. Since 
its discovery, MYH mutations have been associated with 
an attenuated familial adenomatous polyposis (AFAP) 
phenotype in addition to sporadic cancers. Unlike APC 
gene mutations that are expressed in an autosomal dominant 
pattern, the requirement for a biallelic mutation in MYH 
results in an autosomal recessive pattern of inheritance. 
DCC is a tumor-suppressor gene and loss of both alleles is 
required for malignant degeneration. DCC mutations are 
present in more than 70 % of colorectal carcinomas and 
may negatively impact prognosis. 
Aberrant crypt focus (ACF) is morphologically 
abnormal crypt in the colonic mucosa and a real intermediate 
biomarker for colon carcinogenesis [31]. As this lesion is an 
early preneoplastic event for colorectal cancer, it is used for 
short-term bioassays to identify carcinogenesis modulators 
[32-34]. Induction of ACF implies genotoxic events and 
primary DNA damage in colon cells. Thus it is an important 
step for colon cancer chemoprevention. An ACF is darker 
Figure 1: Fearon and Vogelstein’s model for 
the development of colorectal cancer [27].
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than the adjacent crypts when stained with methylene blue 
and is surrounded by thickened epithelium, and also has 
a long and thin lumen. Crypts are 2-3 times larger than 
normal and macroscopically protrude from surrounding 
tissue [35]. Microsatellite instability can be seen. When the 
first mutation belongs to an oncogene (e.g. K-ras) while 
genes such as p53 and APC are intact, the cells gradually go 
to apoptosis to prevent tumor development. 
Finally, the tumor-suppressor gene p53 has been well 
characterized in a number of malignancies. The p53 protein 
appears to be crucial for initiating apoptosis in cells with 
irreparable genetic damage. Mutations in p53 are present 
in 75 % of colorectal cancers [36]. The most important 
step in the transition from adenoma to carcinoma is a p53 
gene mutation [37]. This mutation is defined as a “genome 
keeper” and it is one of the most important regulators of 
the cell cycle. It recognizes defects in DNA and in case 
of unrepaired DNA damage it is responsible for activation 
of genes that take the cell to apoptosis. With deactivation 
in both alleles of this gene transition of an adenoma to a 
carcinoma occurs.
Genotoxic chemicals and models of colon cancer
Chemical carcinogens may be used to create a tumor 
in various organisms. The most widely used chemical 
carcinogens used in models of colon cancer are: 3,2 dimethyl-
4-aminobiphenyl (DMBA), 1,2-dimethyl hydrazine (DMH) 
with azoxymethane (AOM), methylnitrosourea (MNU), 
“N-methyl-N-nitro-N-Nitroguanidine (MNNG) and 
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). 
In order to evaluate the effect of any diet or agent for cancer 
prevention, experimental tumor(s) induced in animals are 
used [38]. For this purpose a carcinogenic agent is given to 
rodents since colon cancer cannot develop spontaneously in 
these rodents. DMH is a commonly used agent and most of 
the published rat studies on tumor induction were done with 
DMH or its metabolite AOM [39]. Due to the difference 
between natural strains and similarity of the disease model 
to human CRC, this model is used to investigate the genetic 
and non-genetic predisposing factors of CRC. 
The risk of developing CRC in inflammatory bowel 
diseases like ulcerative colitis and Crohn’s is higher than 
in the normal population [40]. It has been reported that 
inflammation seen in sporadic CRC and CRC secondary 
to inflammatory bowel disease is associated with increased 
expression of nitric oxide synthase and cyclooxygenase-2 
[41]. Dextran sulfate sodium (DSS) is a non-genotoxic, 
colonic carcinogen that is commonly used to produce a 
form of colitis in rodents that is similar to human ulcerative 
colitis [42]. Colonic inflammation due to exposure to DSS 
and to nitrosative stress are thought to play a role in the 
development of dysplasia and neoplasm of the cryptic 
dysplasia. Thus the inflammatory response alone may lead 
to colon cancer [43]. Initially giving AOM makes the DSS-
induction of colon carcinogenesis faster and may increase 
the incidence of tumors [44].
Anticancer activity of whey proteins
Nutritional studies, reports and trials to identify 
anticancer properties of foods have been extensive. It 
is generally agreed that diets that are high in grains, 
green vegetables, fresh fruit and fiber, and low in total 
and saturated fats are beneficial to health. Relatively less 
emphasis has been placed on bovine milk. Humans who 
consume milk are less likely to develop cancer of the colon 
and rectum than those who do not consume milk. [45,46]. 
Calcium and vitamin D were identified as protective against 
colorectal cancer. Bounous et al. [47, 48] were the first 
to report that whey proteins from bovine milk protect 
against chemically induced carcinogenesis in several animal 
models. There is now enough evidence to suggest that 
bovine milk contains major and minor components with 
anticancer properties [46]. 
Dietary influences on cancer risks have become an 
increasingly important area of research. Prevention of colon 
cancer by dietary whey proteins has been studied in mice 
and rats, but the results are contradictory. McIntosh et al. 
[49] reported that DMH-induced colon tumor incidence 
was reduced in rats fed diets made with either casein or 
whey protein compared with diets made with red meat or 
soy protein. Although there was a tendency toward a lower 
tumor incidence in whey-fed compared to casein-fed rats, 
the difference was not significant and data on tumor mass 
were not consistent. Others showed that whey proteins 
protect more effectively than red meat, soy bean and casein 
against carcinogen-induced colon tumor expression in male 
rats [7, 50]. However, a clear mechanism showing how 
the risk of colon cancer could be reduced by whey protein 
has not been deduced. GSH concentrations in a number 
of tissues have been reported to increase in rats fed whey 
protein, and this is thought to be attributable to relatively 
high levels of γ-glutamylcysteine groups, which serve as 
substrate for glutathione synthetase [48]. The protective 
role of whey proteins is most probably related to the high 
content of cystine/cysteine and γ-glutamylcysteine which 
are efficient substrates for glutathione synthesis [46-48]. 
Other mechanisms for the protective effect of whey 
proteins may be suggested. A protein-fatty acid complex 
consisting of human or bovine whey protein α-lactalbumin 
and the fatty acid oleic acid was reported to have potent 
anticancer properties [51]. In a recent study, it was shown 
that a similar complex may be formed under simulated 
gastric conditions [52]. Tsuda et al. [53] reported that a 
Marmara Medical Journal 2014; 27: 1-6
Yalçın et al.
Whey proteins and colorectal cancer 5
minor whey protein component, bovine lactoferrin, reduced 
the incidence and multiplicity of colon carcinomas in male 
rats. Dietary cysteine-rich proteins had a significant effect 
on the immunological response and on tumor formation in a 
mouse model of colon carcinogenesis [54]. 
In a recent study a whey protein concentrate given 
to breast cancer patients it was suggested that this has a 
protective effect due to elevated antioxidant capacity [55]. 
Whey protein hydrolyzate is the hydrolyzed form of an 
80% whey protein derived from dairy whey processed by 
a special cross-flow filtration process. We have recently 
compared the protective effect of dietary whey protein 
with whey protein hydrolyzate against AOM and DSS 
induced colon cancer in rats [8]. There was a tendency 
toward a lower adenoma incidence in whey-fed compared 
to standard diet-fed rats but the difference was not 
significant. However, in rats fed whey protein hydrolyzate 
the adenoma incidence was significantly decreased. Whey 
protein hydrolyzate prevented colorectal carcinogenesis by 
inhibiting adenoma formation which is the best and most 
relevant marker of CRC. 
CRC begins with ACF at the earliest stage and 
progresses to early adenoma, then to late adenoma, 
then to intramucosal carcinoma and finally to invasive 
adenocarcinoma [33]. A small portion of colorectal 
carcinoma arises de novo starting with epithelial dysplasia, 
then high-grade dysplasia without creating adenoma and 
proceeds to carcinoma. This type of carcinoma can be seen 
in inflammatory diseases such as ulcerative colitis [36]. In 
our study the ulcerative colitis model was created by giving 
DSS. Microscopic examination showed active colitis in all 
rats receiving DSS indicating that whey protein hydrolyzate 
can also prevent colorectal carcinogenesis associated with 
ulcerative colitis and is more effective in preventing colon 
tumor development compared with whey protein [8]. A 
direct association with lipid peroxidation, protein oxidation 
and glutathione was not observed. Other mechanisms may 
also be present. 
Conclusion
Whey protein has been shown to reduce the risk of 
colon cancer and other cancers. The exact mechanism of 
action of whey protein against colon cancer is not clear. It 
was shown that whey protein stimulates the immune system 
by enhancing hepatic glutathione synthesis and can act like 
an antioxidant. The anticancer properties of whey proteins 
may be ascribed to their ability to elevate cellular levels of 
glutathione. Increased tissue concentrations of glutathione 
can be predicted to have a protective effect because elevated 
antioxidant capacity would favor decreased mutagenicity. 
However, further studies are needed to elucidate the exact 
mechanism of action of whey protein against colon cancer.
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